January 3, 2013

MicroPhage seeks bankruptcy protection

LONGMONT – MicroPhage Inc., a Longmont-based company that makes medical tests that can detect staph infections and determine whether they are resistant to antibiotics, has filed for Chapter 11 bankruptcy protection, with debts in excess of $2.3 million.

MicroPhage will attempt to reorganize, according to documents filed Dec. 28 with the Colorado District of the U.S. Bankruptcy Court.

Founded in 2002, MicroPhage develops blood tests that identify bacterial infections. Its first product is the KeyPath MRSA/MSSA blood culture test, which identifies Staphylococcus aureus and whether it is MRSA resistant. MRSA infections do not respond to antibiotics usually prescribed to treat infections and…

Categories:

Related Posts

Sign up for BizWest Daily Alerts
Closing in 8 seconds...